For more than a century, a name carried the weight of a misunderstanding—and 170 million women bore the consequences. The condition long called polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a decade of global research involving 22,000 people across six continents. The renaming, published in The Lancet, reflects a hard-won recognition that what was once framed as a gynecological problem is in fact a systemic hormonal and metabolic disorder—one that shapes a woman's health not just in her reproductive years, but across her entire life.
PCOS Renamed PMOS: A Game-Changing Recognition of Metabolic Disorder
170 million women worldwide experience delayed diagnosis (averaging 2+ years) and inadequate treatment due to misunderstanding of PMOS as primarily a gynecological rather than systemic metabolic disorder.